# Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

> **NCT04717310** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Reistone Biopharma Company Limited** · enrollment: 645 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** SHR0302 Ointment
- **DRUG:** SHR0302 Ointment
- **DRUG:** SHR0302 Ointment
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT04717310
- **Lead sponsor:** Reistone Biopharma Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-30
- **Primary completion:** 2023-09-08
- **Final completion:** 2024-07-14
- **Target enrollment:** 645 (ACTUAL)
- **Last updated:** 2023-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04717310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04717310, "Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04717310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*